| Identification | Back Directory | [Name]
L-Glutamic acid, L-threonyl-L-α-glutamyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-α-glutamyl-L-threonyl-L-valyl-L-α-glutamyl-L-arginyl-L-α-glutamyl-L-lysyl- | [CAS]
174641-44-2 | [Synonyms]
L-Glutamic acid, L-threonyl-L-α-glutamyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-α-glutamyl-L-threonyl-L-valyl-L-α-glutamyl-L-arginyl-L-α-glutamyl-L-lysyl- | [Molecular Formula]
C74H132N26O27 | [MOL File]
174641-44-2.mol | [Molecular Weight]
1818 |
| Hazard Information | Back Directory | [Uses]
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases[1][2]. | [in vivo]
HEP-1 (2.25 mg/kg; intraperitoneal injection; once every two days; from day 1 to day 19) has a protective effect in the DSS (HY-116282C)-induced murine ulcerative colitis model[1]. | Animal Model: | Eight to ten weeks old male C57BL/6 mice (21-23 g) treated DSS (HY-116282C)[1] | | Dosage: | 2.25 mg/kg | | Administration: | Intraperitoneal injection (i.p.); once every two days; from day 1 to day 19 | | Result: | Significantly reduced the body weight loss, DAI score, and mortality rate of the mice.
Inhibited the elevated expression of pro-inflammatory cytokines (such as IL-1β, IL-6, and Nos2) in colon tissues.
significantly reduced the accumulation of Ly6G+ granulocytes and Ly6C+ monocytes in the colon infiltrate.
Prevented the shortening of the colon caused by DSS colitis.
|
| [References]
[1] Chulkina MM, et al. Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes. Peptides. 2020 Oct;132:170364. DOI:10.1016/j.peptides.2020.170364
[2] Holms RD, et al. Ezrin Peptide Therapy from HIV to COVID: Inhibition of Inflammation and Amplification of Adaptive Anti-Viral Immunity. Int J Mol Sci. 2021 Oct 28;22(21):11688. DOI:10.3390/ijms222111688 |
|
|